488 related articles for article (PubMed ID: 26701729)
21. Somatostatin Analogs for Pancreatic Neuroendocrine Tumors: Any Benefit When Ki-67 Is ≥10%?
Merola E; Alonso Gordoa T; Zhang P; Al-Toubah T; Pellè E; Kolasińska-Ćwikła A; Zandee W; Laskaratos F; de Mestier L; Lamarca A; Hernando J; Cwikla J; Strosberg J; de Herder W; Caplin M; Cives M; van Leeuwaarde R
Oncologist; 2021 Apr; 26(4):294-301. PubMed ID: 33301235
[TBL] [Abstract][Full Text] [Related]
22. Ki67 proliferation index, hepatic tumor load, and pretreatment tumor growth predict the antitumoral efficacy of lanreotide in patients with malignant digestive neuroendocrine tumors.
Palazzo M; Lombard-Bohas C; Cadiot G; Matysiak-Budnik T; Rebours V; Vullierme MP; Couvelard A; Hentic O; Ruszniewski P
Eur J Gastroenterol Hepatol; 2013 Feb; 25(2):232-8. PubMed ID: 23108416
[TBL] [Abstract][Full Text] [Related]
23. Treatment efficacy in a metastatic small intestinal neuroendocrine tumour grade 2 cohort.
Papantoniou D; Grönberg M; Thiis-Evensen E; Sorbye H; Landerholm K; Welin S; Tiensuu Janson E
Endocr Relat Cancer; 2023 Mar; 30(3):. PubMed ID: 36629395
[TBL] [Abstract][Full Text] [Related]
24. Impact of Ki67 re-assessment at time of disease progression in patients with pancreatic neuroendocrine neoplasms.
Panzuto F; Cicchese N; Partelli S; Rinzivillo M; Capurso G; Merola E; Manzoni M; Pucci E; Iannicelli E; Pilozzi E; Rossi M; Doglioni C; Falconi M; Delle Fave G
PLoS One; 2017; 12(6):e0179445. PubMed ID: 28644861
[TBL] [Abstract][Full Text] [Related]
25. Octreotide acetate long-acting release in patients with metastatic neuroendocrine tumors pretreated with lanreotide.
Ricci S; Antonuzzo A; Galli L; Ferdeghini M; Bodei L; Orlandini C; Conte PF
Ann Oncol; 2000 Sep; 11(9):1127-30. PubMed ID: 11061606
[TBL] [Abstract][Full Text] [Related]
26. Somatostatin analogues in functioning gastroenteropancreatic neuroendocrine tumours: literature review, clinical recommendations and schedules.
Massironi S; Conte D; Rossi RE
Scand J Gastroenterol; 2016; 51(5):513-23. PubMed ID: 26605828
[TBL] [Abstract][Full Text] [Related]
27. INITIATION OF PATIENTS ONTO LONG-ACTING SOMATOSTATIN ANALOGUE THERAPY FOR NEUROENDOCRINE TUMORS: A SINGLE-CENTER REVIEW OF PRACTICE.
Tadman M; Charlton P; Jafar-Mohammadi B; Talbot D; Grossman AB
Endocr Pract; 2018 Feb; 24(2):189-194. PubMed ID: 29466059
[TBL] [Abstract][Full Text] [Related]
28. Neuroendocrine tumours - Medical therapy: Biological.
Rinke A; Krug S
Best Pract Res Clin Endocrinol Metab; 2016 Jan; 30(1):79-91. PubMed ID: 26971845
[TBL] [Abstract][Full Text] [Related]
29. The value of the Ki-67 proliferation marker as a prognostic factor in gastroenteropancreatic neuroendocrine tumours.
Foltyn W; Zajęcki W; Marek B; Kajdaniuk D; Siemińska L; Zemczak A; Kos-Kudła B
Endokrynol Pol; 2012; 63(5):362-6. PubMed ID: 23115069
[TBL] [Abstract][Full Text] [Related]
30. Therapeutic sequences in patients with grade 1-2 neuroendocrine tumors (NET): an observational multicenter study from the ELIOS group.
Faggiano A; Di Maio S; Mocerino C; Ottaviano M; De Divitiis C; Guarnotta V; Dolce P; Modica R; Puliafito I; Tozzi L; Di Sarno A; Leo S; Riccardi F; Palmieri G; Tafuto S; Bianco A; Badalamenti G; Colao A;
Endocrine; 2019 Nov; 66(2):417-424. PubMed ID: 30875056
[TBL] [Abstract][Full Text] [Related]
31. External Validity of Somatostatin Analogs Trials in Advanced Neuroendocrine Neoplasms: The GETNE-TRASGU Study.
Jimenez-Fonseca P; Carmona-Bayonas A; Lamarca A; Barriuso J; Castaño A; Benavent M; Alonso V; Riesco MDC; Alonso-Gordoa T; Custodio A; Sanchez Canovas M; Hernando J; López C; La Casta A; Fernandez Montes A; Marazuela M; Crespo G; Diaz JA; Feliciangeli E; Gallego J; Llanos M; Segura A; Vilardell F; Percovich JC; Grande E; Capdevila J; Valle J; Garcia-Carbonero R
Neuroendocrinology; 2022; 112(1):88-100. PubMed ID: 33508849
[TBL] [Abstract][Full Text] [Related]
32. Ki-67 index and response to chemotherapy in patients with neuroendocrine tumours.
Childs A; Kirkwood A; Edeline J; Luong TV; Watkins J; Lamarca A; Alrifai D; Nsiah-Sarbeng P; Gillmore R; Mayer A; Thirlwell C; Sarker D; Valle JW; Meyer T
Endocr Relat Cancer; 2016 Jul; 23(7):563-70. PubMed ID: 27412968
[TBL] [Abstract][Full Text] [Related]
33. The expanding role of somatostatin analogs in gastroenteropancreatic and lung neuroendocrine tumors.
Cives M; Strosberg J
Drugs; 2015 May; 75(8):847-58. PubMed ID: 25911185
[TBL] [Abstract][Full Text] [Related]
34. Phase II clinical trial of pasireotide long-acting repeatable in patients with metastatic neuroendocrine tumors.
Cives M; Kunz PL; Morse B; Coppola D; Schell MJ; Campos T; Nguyen PT; Nandoskar P; Khandelwal V; Strosberg JR
Endocr Relat Cancer; 2015 Feb; 22(1):1-9. PubMed ID: 25376618
[TBL] [Abstract][Full Text] [Related]
35. Outcome of Patients With Metastatic Lung Neuroendocrine Tumors Submitted to First Line Monotherapy With Somatostatin Analogs.
Lenotti E; Alberti A; Spada F; Amoroso V; Maisonneuve P; Grisanti S; Baggi A; Bianchi S; Fazio N; Berruti A
Front Endocrinol (Lausanne); 2021; 12():669484. PubMed ID: 33986731
[TBL] [Abstract][Full Text] [Related]
36. Long-acting somatostatin analogues in the treatment of unresectable/metastatic neuroendocrine tumors.
Enzler T; Fojo T
Semin Oncol; 2017 Apr; 44(2):141-156. PubMed ID: 28923213
[TBL] [Abstract][Full Text] [Related]
37. Antitumour activity of somatostatin analogues in sporadic, progressive, metastatic pulmonary carcinoids.
Sullivan I; Le Teuff G; Guigay J; Caramella C; Berdelou A; Leboulleux S; Déandréis D; Hadoux J; Ducreux M; Duvillard P; Adam J; Scoazec JY; Baudin E; Planchard D
Eur J Cancer; 2017 Apr; 75():259-267. PubMed ID: 28242503
[TBL] [Abstract][Full Text] [Related]
38. Clinical validation of the gastrointestinal NET grading system: Ki67 index criteria of the WHO 2010 classification is appropriate to predict metastasis or recurrence.
Yamaguchi T; Fujimori T; Tomita S; Ichikawa K; Mitomi H; Ohno K; Shida Y; Kato H
Diagn Pathol; 2013 Apr; 8():65. PubMed ID: 23607525
[TBL] [Abstract][Full Text] [Related]
39. The high-grade (WHO G3) pancreatic neuroendocrine tumor category is morphologically and biologically heterogenous and includes both well differentiated and poorly differentiated neoplasms.
Basturk O; Yang Z; Tang LH; Hruban RH; Adsay V; McCall CM; Krasinskas AM; Jang KT; Frankel WL; Balci S; Sigel C; Klimstra DS
Am J Surg Pathol; 2015 May; 39(5):683-90. PubMed ID: 25723112
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of the efficacy and safety of lanreotide in combination with targeted therapies in patients with neuroendocrine tumours in clinical practice: a retrospective cross-sectional analysis.
Capdevila J; Sevilla I; Alonso V; Antón Aparicio L; Jiménez Fonseca P; Grande E; Reina JJ; Manzano JL; Alonso Lájara JD; Barriuso J; Castellano D; Medina J; López C; Segura Á; Carrera S; Crespo G; Fuster J; Munarriz J; García Alfonso P
BMC Cancer; 2015 Jul; 15():495. PubMed ID: 26138480
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]